Oncology Intelligence — July 07, 2026
|
Novartis is paying $1.1 billion upfront — up to $1.5 billion with milestones — for Myricx Bio’s NMT-inhibitor ADC platform, its most decisive move yet to break into a saturated antibody-drug conjugate market, while Bristol Myers Squibb’s Krazati stumbles in colorectal cancer and Roche remakes its early oncology research model.
Today’s top developments:
|
What to Watch
- FDA response to Krazati’s CRC data — a withdrawal request or label restriction would mark the first post-accelerated-approval rollback in KRAS G12C inhibition and reset Amgen sotorasib’s commercial expectations upward.
- First clinical proof-of-concept for Myricx’s NMT-inhibitor payloads — the up-to-$1.5B deal value hinges on Phase 1 data showing differentiated tumor kill without the resistance mechanisms limiting topoisomerase-I conjugates.
- Targets emerging from the Genentech–Astex breast cancer pact — this discovery-stage collaboration (up to $490M in milestones) is early; watch for the specific molecular targets and lead programs to surface as it matures.
- JNJ-79635322 versus teclistamab enrollment — the head-to-head in NCT07518186 is the key myeloma bispecific trial to track through 2026, with interim data potentially reordering Janssen’s internal myeloma priorities.
This brief highlights the edition’s top stories. Read the full July 7, 2026 edition → for all stories and analysis — or browse the Oncology archive.